Spots Global Cancer Trial Database for dovitinib
Every month we try and update this database with for dovitinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | NCT01753713 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | dovitinib laboratory biom... | 18 Years - | Case Comprehensive Cancer Center | |
| Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib | NCT01478373 | Gastrointestina... | Dovitinib (TKI2... | 18 Years - | Novartis | |
| Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function | NCT01443481 | Solid Tumors Hepatic Impairm... | Dovitinib | 18 Years - | Novartis | |
| Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function | NCT01443481 | Solid Tumors Hepatic Impairm... | Dovitinib | 18 Years - | Novartis | |
| Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 | NCT01440959 | Gastrointestina... | dovitinib | 20 Years - | Asan Medical Center | |
| 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC | NCT01791387 | Clear Cell Rena... | Dovitinib | 18 Years - | Auckland District Health Board | |
| Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma | NCT01972750 | First or Second... | Dovitinib | 18 Years - 100 Years | University Hospital, Bonn | |
| Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer | NCT01484041 | Breast Cancer | Dovitinib Aromatase Inhib... | 18 Years - | Georgetown University | |
| Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | NCT01223027 | Metastatic Rena... | Dovitinib Sorafenib | 18 Years - | Novartis | |
| Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer | NCT01861197 | Squamous NSCLC | Dovitinib | 20 Years - | Samsung Medical Center | |
| Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma | NCT01680796 | Multiple Myelom... | Dovitinib Bortezomib Dexamethasone | 18 Years - | University of Florida | |
| A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy | NCT01769547 | Advanced Malign... MPM | Dovitinib | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors | NCT01548924 | Solid Tumors | Dovitinib Dovitinib + Pac... | 18 Years - 76 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | |
| Dovitinib in Adenoid Cystic Carcinoma | NCT01417143 | Adenoid Cystic ... | TKI258 (Dovitin... | 18 Years - | Seoul National University Hospital | |
| TKI 258 in Von Hippel-Lindau Syndrome (VHL) | NCT01266070 | Von Hippel-Lind... | Dovitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma | NCT01680796 | Multiple Myelom... | Dovitinib Bortezomib Dexamethasone | 18 Years - | University of Florida | |
| Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib | NCT01831726 | Tumor Pathway A... | Dovitinib (TKI2... | 18 Years - 100 Years | Novartis | |
| A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment | NCT01232296 | Hepatocellular ... | dovitinib sorafenib | 18 Years - | Novartis | |
| Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer | NCT01528345 | Metastatic Brea... | Dovitinib Fulvestrant Dovitinib Place... | 18 Years - | Novartis | |
| Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer | NCT01714765 | Metastatic Clea... | Dovitinib Everolimus | 18 Years - | Queen Mary University of London | |
| Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma | NCT01514526 | Adrenocortical ... | Dovitinib | 18 Years - | Spanish Oncology Genito-Urinary Group | |
| An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer | NCT01964144 | Thyroid Cancer | Dovitinib | 20 Years - 90 Years | Yonsei University | |
| TKI258 for Metastatic Inflammatory Breast Cancer Patients | NCT01262027 | Breast Cancer | Dovitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1 | NCT01719549 | Gastric Cancer | Dovitinib | 18 Years - | Asan Medical Center | |
| Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function | NCT01443481 | Solid Tumors Hepatic Impairm... | Dovitinib | 18 Years - | Novartis | |
| Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression | NCT01732107 | Bladder Cancer | Dovitinib | 18 Years - | Hoosier Cancer Research Network | |
| An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer | NCT01964144 | Thyroid Cancer | Dovitinib | 20 Years - 90 Years | Yonsei University | |
| Dovitinib in Adenoid Cystic Carcinoma | NCT01417143 | Adenoid Cystic ... | TKI258 (Dovitin... | 18 Years - | Seoul National University Hospital | |
| Dovitinib in Neuroendocrine Tumors | NCT01635907 | Advanced Metast... Advanced Metast... Recurrent Parag... Recurrent Pheoc... Unresectable Pa... Unresectable Ph... | Dovitinib | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment | NCT01232296 | Hepatocellular ... | dovitinib sorafenib | 18 Years - | Novartis | |
| Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | NCT01223027 | Metastatic Rena... | Dovitinib Sorafenib | 18 Years - | Novartis | |
| Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | NCT01753713 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | dovitinib laboratory biom... | 18 Years - | Case Comprehensive Cancer Center | |
| Maintenance Dovitinib for Colorectal and Pancreas Cancer | NCT01888965 | Colorectal Canc... Pancreas Cancer | Dovitinib | 18 Years - | Georgetown University | |
| Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1 | NCT01719549 | Gastric Cancer | Dovitinib | 18 Years - | Asan Medical Center | |
| A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands | NCT01678105 | Recurrent Adeno... Metastatic Aden... Salivary Gland ... ACC | Dovitinib | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer | NCT01484041 | Breast Cancer | Dovitinib Aromatase Inhib... | 18 Years - | Georgetown University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
